Norstella

Scrip Podcasts

Scrip delivers expert-driven audio insight on biopharma — from R&D, commercial strategy and deal activity to coverage of major industry events. Every Monday, Ian Haydock presents Quick Listen: Five Must-Know Things, a weekly roundup of top industry stories. Joseph Haas hosts a quarterly deep-dive into dealmaking with guests from leading companies, law firms and investment firms. Visit https://insights.citeline.com/scrip to sign up.

Vizitează neapărat site-ul podcastului și susține-i creatorul: insights.citeline.com

Autor

Norstella

Categorie

Business

Site-ul podcastului

insights.citeline.com

Cel mai nou episod

19 nov. 2026

Unde asculți?

Podcasturi în aplicație Replaio Radio În curând

Podcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor

Descarcă din Google Play Instalează gratuit Android 10 mil.+ descărcări · nota 4,7+ iOS în curând

Episoade

Due Diligence Podcast: Why Are Reverse Mergers Increasing Despite Rising IPO Activity 19.11.2026

Biotech execs Matt Davidson and Sheila Gujrathi and attorney Mike Blankenship join Scrip’s Joseph Haas to discuss the uptick of reverse mergers in 2026 and the factors driving that trend.

Strategic Intent: Praxis CEO On Unlearning, AI And Launching Two Neuroscience Drugs At Once 17.11.2026

Praxis Precision Medicines is within weeks of FDA decisions on two potential firsts: relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, and ulixacaltamide for essential tremor. In this episode of Strategic Intent, In Vivo senior reporter David Wild talks with Praxis CEO Marcio Souza about the company’s philosophy of “unlearning,” how AI is embedded across the organizatio...

Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) 16.11.2026

本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年11月13日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括:Rasonque的惊艳上市;行业资深人士分享合作智慧;Lp(a)药物市场前景黯淡;ACR会议上细胞疗法展现希望;以及Teva的创新雄心。 Story links here. 向听众们简要更新一下:Scrip 现在已在 Spotify 和 Apple Podcasts 上开设了专属播客频道...

Scrip's Five Must-Know Things - Rasonque's Stellar Launch, Biotech Partnering Tips and Teva's Innovation Pivot 16.11.2026

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Nov. 13, 2026. This time—Rasonque’s stellar launch; veterans share partnering wisdom; pessimism over Lp(a) drugs; cell therapy promise at ACR; and Te...

Strategic Intent: Lundbeck On Reimbursement, Risk And The Return Of Neuroscience 10.11.2026

In this episode of Strategic Intent, Maria Alfaiate, Executive Vice President for Corporate Portfolio and Product Strategy at Lundbeck, discusses neuroscience's growing resurgence in pharmaceutical investment alongside other challenges faced in central nervous system dealmaking decisions.

Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) 09.11.2026

本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年11月6日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括:马德里加尔公司(Madrigal)的MASH项目举报人;礼来(Lilly)将继续推进并购;赛诺菲(Sanofi)正在寻求后期研发资产;辉瑞(Pfizer)上调业绩预期;以及LIB公司PCSK9药物的定价。 Story links here. 向听众们简要更新一下:Scrip 现在已在 Spotify&nbsp...

Scrip's Five Must-Know Things: Madrigal Whistleblower Case, Lilly & Sanofi Hunting Deals 09.11.2026

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Nov. 6, 2026. This time—Madrigal’s MASH whistleblower; Lilly’s dealmaking to continue; Sanofi hunting late-stage assets; Pfizer raises guidance; and...

Proof of Concept: The Money Is Back In RNA, But What Stands Between Headlines And Routine Medicine? 06.11.2026

"The money is back in RNA. In recent weeks, Merck KGaA agreed to pay about $1.1 billion for Silence Therapeutics, Novartis signed a deal worth up to $7.8 billion with Abogen Biosciences, and Roche paid more than $1 billion for an RNAi obesity drug from Rona Therapeutics. Meanwhile, Merck and Moderna’s personalized melanoma vaccine cut the risk of recurrence or death by 42% in a Phase 3 trial. So,...

Rethinking Risk: Why Early Evidence Strategy Matters for Emerging Biotechs 02.11.2026

For emerging biotech companies, development success is often measured by clinical milestones, safety, and efficacy. However, demonstrating an asset’s value extends beyond regulatory approval. Understanding patient needs and treatment experiences, as well as evolving stakeholder expectations, early in development plays an important role in shaping a more informed evidence strategy. In this podcast,...

Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) 02.11.2026

本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年10月30日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括:美国《COINS法案》的影响;葛兰素史克(GSK)在肿瘤领域的业务转型;礼来(Lilly)在KRAS领域的推进;ris-rez为骨肉瘤治疗带来新希望;以及Genmab最新III期临床试验的胜利。 Story links here. 向听众们简要更新一下:Scrip 现在已在 Spotify 和&n...

Scrip's Five Must-Know Things: US COINS Impact, GSK's Oncology Turnaround, Lilly's KRAS Push 02.11.2026

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 30, 2026. This time—US COINS Act impact; GSK’s oncology turnaround; Lilly’s KRAS push; ris-rez gives new hope in osteosarcoma; and Genmab’s late...

Scrip's Five Must-Know Things: Key ESMO Readouts, Next-Gen ADCs And Mid-Cap Winners 26.10.2026

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 23, 2026. This time—key expectations from ESMO meeting; next-generation antibody-drug conjugates; rising mid-cap stars; GSK's novel hepatitis B...

Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.26, 2026 26.10.2026

本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年10月23日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括:欧洲肿瘤内科学会(ESMO)会议的关键预期;新一代抗体药物偶联物;冉冉升起的中盘股新星;葛兰素史克(GSK)新型乙肝药物的上市;以及私营企业的重大融资动态。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/sc...

Scrip Awards Podcast – Parabilis CEO Mathai Mammen Interview 22.10.2026

Ahead of the awards presentation on Dec 2, the Scrip Awards podcast speaks to Mathai Mammen, CEO of Parabilis, one of the shortlisted companies for Biotech of The Year.

Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.19, 2026 19.10.2026

本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年10月16日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括:Tremfya从Stelara的余烬中崛起;辉瑞将成熟品牌作为试验田;中国科研力量在第三季度交易中大放异彩;Argenx在自身免疫领域取得进展与遭遇挫折;日本力图重振生物制药竞争力。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-k...

Scrip's Five Must-Know Things - Oct. 19, 2026 19.10.2026

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 16, 2026. This time—Tremfya rises from Stelara’s ashes; Pfizer uses mature brands as testbeds; Chinese science shines in Q3 deals; autoimmune wi...

Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.14, 2026 15.10.2026

本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年10月9日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本周内容包括:中国带来的竞争威胁;第三季度并购活动降温;新型肺炎球菌疫苗竞争者;西班牙生物技术公司的战略;以及盐野义制药20亿美元的收购案。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know...

Scrip's Five Must-Know Things - Oct. 13, 2026 13.10.2026

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 9, 2026. This time—China’s competitive threat; M&As cool off in Q3; new pneumococcal vaccine contender; strategy for Spanish biotechs; and Shionogi’s...

Rethinking Success in Neuroscience Clinical Development 12.10.2026

Despite significant scientific progress in neuroscience, clinical trial success rates remain low. Complex diseases, evolving therapeutic approaches and challenges around endpoint selection continue to make development difficult. As biomarkers, AI and precision medicine become increasingly integrated into clinical research, sponsors have new opportunities to strengthen study design, improve patient...

Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.5, 2026 05.10.2026

本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年10月2日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 谁在引领今年的并购步伐;罗氏(Roche)的研发管线重整;湿性黄斑变性(wet AMD)市场的洗牌;默克公司(Merck & Co.)撤回I-DXd申报;以及默克将Recarbio从市场上撤回。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/qui...

Scrip's Five Must-Know Things - Oct. 5, 2026 05.10.2026

Audio roundup of selected biopharma industry content from Scrip over the business week ended Oct. 2, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—who’s setting the M&A pace this year; Roche’s pipeline reset; wet AMD market shakeup; Merck & Co. pulls I-DXd filing; and Merck withdraws Recarbio from the market.  Story links: https://insig...

Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Sept. 25, 2026 28.09.2026

本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年9月25日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 中国带来的变革效应;诺和诺德的新战略;罗氏的抗肥胖新药;安进在舍格伦综合征治疗领域的胜利;以及中国潜在的重磅药物。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WVD7A...

Scrip's Five Must-Know Things - Sept. 28, 2026 28.09.2026

Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 25, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—China’s transforming effect; Novo’s new strategy; Roche’s obesity contender; Amgen’s Sjögren’s win; and potential Chinese blockbusters.  Story links: https://insights.citeline.com/scrip/pod...

Assessing the current dealmaking environment for psychedelic medicine. 24.09.2026

Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways' COMP360 for treatment-resistant depression and a more relaxed regulatory environment for psychedelic therapies under the current administration.

Scrip's Five Must-Know Things - Sept, 14, 2026 14.09.2026

Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 11, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—what’s next in cardiovascular R&D following recent Phase III failures; sequential gains for nine of the world’s 10 best-selling drugs in Q2; AstraZeneca’s first-in-class COPD contender out-perfo...

Ascultă podcastul Scrip Podcasts în Replaio

Radio și podcasturi într-o singură aplicație - gratuit și fără înregistrare. Instaleaz-o azi și nu rata lansarea

Descarcă din Google Play

Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice